SCHEMBL89015

SCHEMBL89015

COCCCOc1ccc(C(=O)NC2CC2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.55
PDE4A P27815 2/20 0.53
PDE4B Q07343 2/20 0.53
PDE4C Q08493 2/20 0.53
PDE4D Q08499 2/20 0.53
MAPK14 Q16539 1/20 0.53
SMPD1 P17405 4/20 0.52
MEN1 O00255 1/20 0.52
ALPL P05186 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
MCHR1 Q99705 1/20 0.51
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
APOBEC3G Q9HC16 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL90498 0.95 CNR2 (0.61) CNR2PDE4APDE4BPDE4CPDE4D
SCHEMBL2473674 0.86 MEN1 (0.65) CNR2PDE4APDE4BPDE4CPDE4D
SCHEMBL2087745 0.86 LRRK2 (0.49) CNR2MAPK14MEN1KMT2AHPGD
SCHEMBL11244433 0.85 SMPD1 (0.63) CNR2SMPD1MEN1ALPLKMT2A
Hydrochloric Acid SCHEMBL9639296 0.85 MEN1 (0.64) CNR2PDE4APDE4BPDE4CPDE4D
SCHEMBL90493 0.84 HTR7 (0.50) CNR2MAPK14ALDH1A1HPGDRAB9A
SCHEMBL8238436 0.84 MAPK14 (0.52) CNR2MAPK14MEN1ALPLKMT2A
SCHEMBL30683868 0.82 TSHR (0.69)
SCHEMBL89386 0.82 TSHR (0.69)
SCHEMBL11687058 0.81 KMT2A (0.74) MEN1ALPLKMT2ACYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 CNR2 1820/4885PDE4A 835/4885PDE4B 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.